VEGFA and central nervous system cancer: Another FDA-approved drug for the treatment of recurrent gliomas is bevacizumab, which is an anti-angiogenic monoclonal antibody that works by attaching to vascular endothelial growth factor (VEGF), thereby inhibiting its ability to bind to receptors on the surface of endothelial cells.